Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES: This study investigated whether Janus kinase inhibitors (JAKis) raise the risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and cancer in patients with rheumatoid arthritis (RA). METHODS: We conducted a real-world retrospective observational study using data obtained from the Korean National Health Insurance Service database. Two data sets were analyzed: tumor necrosis factor inhibitor (TNFi)/JAKi-naive RA patients (set 1) and all RA patients who used TNFis or JAKis (set 2). The incidence rate ratios (IRRs) and hazard ratios (HRs) for acute myocardial infarction (AMI), stroke, cardiovascular (CV)-related mortality, major adverse cardiovascular events (MACE), VTE, arterial thromboembolism (ATE), cancer, and all-cause mortality were compared between the JAKi and TNFi groups. RESULTS: Set 1 included 1,596 RA patients (JAKi group: 645; TNFi group: 951), and set 2 included 11,765 RA patients (JAKi group: 2,498; TNFi group: 9,267). No adverse events (AEs) showed significantly higher IRRs in the JAKi groups than in the TNFi groups of sets 1 and 2. The HRs for MACE in the JAKi groups of sets 1 and 2 were 0.59 (95% confidence [CI], 0.35 to 0.99) and 0.80 (95% CI, 0.67 to 0.97), respectively. The JAKi group of set 2 showed a significantly higher risk of all-cause mortality (HR, 1.71; 95% CI, 1.32 to 2.20), but the other AEs did not demonstrate increased risks in the JAKi groups. CONCLUSIONS: In this study, JAKis did not increase the risk of AMI, stroke, CV-related mortality, MACE, VTE, ATE, or cancer in Korean RA patients relative to TNFis.
Abstract
OBJECTIVES: This study investigated whether Janus kinase inhibitors (JAKis) raise the risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and cancer in patients with rheumatoid arthritis (RA). METHODS: We conducted a real-world retrospective observational study using data obtained from the Korean National Health Insurance Service database. Two data sets were analyzed: tumor necrosis factor inhibitor (TNFi)/JAKi-naive RA patients (set 1) and all RA patients who used TNFis or JAKis (set 2). The incidence rate ratios (IRRs) and hazard ratios (HRs) for acute myocardial infarction (AMI), stroke, cardiovascular (CV)-related mortality, major adverse cardiovascular events (MACE), VTE, arterial thromboembolism (ATE), cancer, and all-cause mortality were compared between the JAKi and TNFi groups. RESULTS: Set 1 included 1,596 RA patients (JAKi group: 645; TNFi group: 951), and set 2 included 11,765 RA patients (JAKi group: 2,498; TNFi group: 9,267). No adverse events (AEs) showed significantly higher IRRs in the JAKi groups than in the TNFi groups of sets 1 and 2. The HRs for MACE in the JAKi groups of sets 1 and 2 were 0.59 (95% confidence [CI], 0.35 to 0.99) and 0.80 (95% CI, 0.67 to 0.97), respectively. The JAKi group of set 2 showed a significantly higher risk of all-cause mortality (HR, 1.71; 95% CI, 1.32 to 2.20), but the other AEs did not demonstrate increased risks in the JAKi groups. CONCLUSIONS: In this study, JAKis did not increase the risk of AMI, stroke, CV-related mortality, MACE, VTE, ATE, or cancer in Korean RA patients relative to TNFis.
참고문헌 (38)
- Smolen JS, "Rheumatoid arthritis", Nat Rev Dis Primers, 4, pp.18001~ (2018)
- Widdifield J, "Causes of death in rheumatoid arthritis: how do they compare to the general population?", Arthritis Care Res, 70, pp.1748~1755 (2018)
- Luque Ramos A, "Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes : results of claims data linked to questionnaire survey", J Rheumatol, 46, pp.564~571 (2019)
- van den Hoek J, "Mortality in patients with rheumatoid arthritis : a 15-year prospective cohort study", Rheumatol Int, 37, pp.487~493 (2017)
- Kim SC, "Risk of venous thromboembolism in patients with rheumatoid arthritis", Arthritis Care Res(Hoboken), 65, pp.1600~1607 (2013)
- Desai RJ, "Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors : an observational cohort study", Arthritis Rheumatol, 71, pp.892~900 (2019)
- Nurmohamed MT, "Cardiovascular comorbidity in rheumatic diseases", Nat Rev Rheumatol, 11, pp.693~704 (2015)
- Aletaha D, "Diagnosis and management of rheumatoid arthritis : a review", JAMA, 320, pp.1360~1372 (2018)
- 박은정, "The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus", 대한류마티스학회지, 27(1), pp.4~21 (2020), 대한류마티스학회[DOI]
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update", Ann Rheum Dis, 79, pp.685~699 (2020)
- Fraenkel L, "2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Rheumatol, 73, pp.1108~1123 (2021)
- Ytterberg SR, "Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis", N Engl J Med, 386, pp.316~326 (2022)
- Khosrow-Khavar F, "Tofacitinib and risk of cardiovascular outcomes : results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis(STAR-RA)study", Ann Rheum Dis, 81, pp.798~804 (2022)
- Hoisnard L, "Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab : a nationwide cohort study", Ann Rheum Dis, 82, pp.182~188 (2023)
- Charles-Schoeman C, "Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease : a post hoc analysis from ORAL Surveillance", Ann Rheum Dis, 82, pp.119~129 (2023)
- Seong SC, "Data resource profile : the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
- Cho SK, "Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database", Rheumatol Int, 33, pp.2985~2992 (2013)
- White WB, "Cardiovascular safety of febuxostat or allopurinol in patients with gout", N Engl J Med, 378, pp.1200~1210 (2018)
- Mackenzie IS, "Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout(FAST) : a multicentre, prospective, randomised, open-label, non-inferiority trial", Lancet, 396, pp.1745~1757 (2020)
- Aviña-Zubieta JA, "Risk of cardiovascular mortality in patients with rheumatoid arthritis : a meta-analysis of observational studies", Arthritis Rheum, 59, pp.1690~1697 (2008)
- Avina-Zubieta JA, "Risk of incident cardiovascular events in patients with rheumatoid arthritis : a meta-analysis of observational studies", Ann Rheum Dis, 71, pp.1524~1529 (2012)
- Hsieh MJ, "Biologic agents reduce cardiovascular events in rheumatoid arthritis not responsive to tumour necrosis factor inhibitors : a national cohort study", Can J Cardiol, 36, pp.1739~1746 (2020)
- Jin Y, "Cardiovascular(CV)risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease", J Rheumatol, 45, pp.1240~1248 (2018)
- Xie F, "Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients", Arthritis Care Res(Hoboken), 71, pp.1004~1018 (2019)
- Kang EH, "Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus : a multidatabase cohort study", J Am Heart Assoc, 7, pp.e007393~ (2018)
- Zhang J, "Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis", Ann Rheum Dis, 75, pp.1813~1818 (2016)
- Kim SC, "No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis : a multi-database cohort study", Semin Arthritis Rheum, 48, pp.399~405 (2018)
- Ozen G, "The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis", J Rheumatol, 48, pp.648~655 (2021)
- Lee JL, "Biologics and cardiovascular events in inflammatory arthritis : a prospective national cohort study", Arthritis Res Ther, 20, pp.171~ (2018)
- Greenberg JD, "Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis", Ann Rheum Dis, 70, pp.576~582 (2011)
- Arts EE, "The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients", Ann Rheum Dis, 74, pp.998~1003 (2015)
- Xie W, "Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis : systematic review and meta-analysis of randomised controlled trials", Ann Rheum Dis, 78, pp.1048~1054 (2019)
- "Health, United States spotlight racial and ethnic disparities in heart disease" (2019)[URL]
- Hu LJ, "Venous thromboembolism risk in rheumatoid arthritis patients : a systematic review and updated meta-analysis", Eur Rev Med Pharmacol Sci, 25, pp.7005~7013 (2021)
- Yates M, "Venous thromboembolism risk with JAK inhibitors : a meta-analysis", Arthritis Rheumatol, 73, pp.779~788 (2021)
- Solipuram V, "Effect of Janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis : a systematic review and meta-analysis of randomized controlled trials", Auto Immun Highlights, 12, pp.8~ (2021)
- Ward E, "Cancer disparities by race", ethnicity and socioeconomic status, 2004, pp.54, 78~93
- Parise CA, "Regional variation in disparities in breast cancer specific mortality due to race", ethnicity, socioeconomic status, and urbanization, 2017, pp.4, 706~717